Overview

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative risks and benefits of two approaches to the control of weight gain and other negative side effects in children and adolescents on 2nd generation antipsychotics (SGA): - Healthy lifestyle instruction (nutritional and physical activity surveillance and advice) + continuation of current SGA; - Add the diabetes drug, metformin + continuation of current SGA.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
Foundation of Hope, North Carolina
Treatments:
Antipsychotic Agents
Aripiprazole
Clozapine
Metformin
Ziprasidone